Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

1.8K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

5.9K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

HPV awareness gaps and the significant economic burden of oropharyngeal cancer in Ireland.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Potential Clinical Impact of Sinonasal Biofilms in CRS: A Structured Evidence Synthesis.

International forum of allergy & rhinology·2026
Same author

Surgical site infections in the returning medical tourist: bridging the knowledge gap and identifying areas for improvement.

The Journal of hospital infection·2026
Same author

Explainable multi-agent learning for adaptive terrorist network disruption.

Scientific reports·2026
Same author

Plasma exchange aids thyroidectomy in refractory amiodarone-induced thyrotoxicosis, despite variable biochemical responses.

European thyroid journal·2026
Same author

Tumour-infiltrating lymphocytes do not predict survival in human papillomavirus-associated oropharyngeal squamous cell carcinoma: a single institution retrospective review.

The Journal of laryngology and otology·2026

Related Experiment Video

Updated: Jan 16, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.7K

Merkel Cell Carcinoma: Evolving Therapeutics, Continued Challenges.

Hunter A Holley1, Maria Lyons2,3, Barry O'Sullivan4

  • 1Department of Graduate Entry Medicine, Royal College of Surgeons in Ireland (RCSI), Dublin, Ireland.

Head & Neck
|September 27, 2025
PubMed
Summary

Merkel Cell Carcinoma (MCC) management has advanced with immune checkpoint inhibitors (ICIs), improving survival for virus-positive cases. However, high recurrence rates necessitate ongoing surveillance and research into combination therapies.

Keywords:
Merkel Cell Carcinomaimmunotherapypathogenesisprognosistherapeutics

More Related Videos

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

12.2K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

1.3K

Related Experiment Videos

Last Updated: Jan 16, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.7K
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

12.2K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

1.3K

Area of Science:

  • Oncology
  • Immunology
  • Virology

Background:

  • Merkel Cell Carcinoma (MCC) is a rare, aggressive neuroendocrine cancer with increasing incidence.
  • Risk factors include ultraviolet (UV) radiation exposure and Merkel cell polyomavirus (MCPyV) infection.

Purpose of the Study:

  • To review recent advancements in MCC treatment strategies.
  • To analyze the impact of viral status and immune checkpoint inhibitors (ICIs) on patient outcomes.

Main Methods:

  • Literature review of current research on MCC management.
  • Analysis of data on immune checkpoint inhibitors, viral status, and multimodal therapies.

Main Results:

  • MCPyV-positive MCC shows significantly better median overall survival (6.6 years) than virus-negative MCC (1.2 years).
  • Immune checkpoint inhibitors like avelumab and pembrolizumab have markedly improved survival rates for metastatic MCC.
  • Pembrolizumab demonstrated a median OS of 24.3 months and a median PFS of 9.3 months.

Conclusions:

  • Despite treatment progress, MCC recurrence rates remain substantial, underscoring the need for long-term patient monitoring.
  • Future research should explore optimized combination therapies, predictive biomarkers, and refined treatment sequencing to enhance survival and quality of life.